Preferred Label : Auranofin;
NCIt definition : An orally available, lipophilic, organogold compound, used to treat rheumatoid arthritis,
with anti-inflammatory and potential antineoplastic activities. Auranofin interacts
with selenocysteine residue within the redox-active domain of mitochondrial thioredoxin
reductase (TrxR), thereby blocking the activity of TrxR. As a result, this agent induces
mitochondrial oxidative stress leading to the induction of apoptosis. Furthermore,
this agent strongly inhibits the JAK1/STAT3 signal transduction pathway, thereby suppressing
expression of immune factors involved in inflammation. TrxR, overexpressed in many
cancer cell types, inhibits apoptosis, promotes cell growth and survival and plays
a role in resistance to chemotherapy; TrxR catalyzes the reduction of oxidized thioredoxin
(Trx) and plays a central role in regulating cellular redox homeostasis.;
UNII : 3H04W2810V;
InChIKey : AUJRCFUBUPVWSZ-XTZHGVARSA-M;
CAS number : 34031-32-8;
Drug name : Ridaura;
Chemical formula : C20H34AuO9PS;
ChEBI ID : CHEBI:2922;
Origin ID : C65242;
UMLS CUI : C0004320;
Currated CISMeF NLP mapping
Semantic type(s)
UMLS correspondences (same concept)
Validated automatic mappings to BTNT
concept_is_in_subset
has_target